Johnson & Johnson(JNJ)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Latest News & Analysis
Halda Acquisition Validates JNJ's Pharma-Focused Capital Discipline
JNJ's $3.05B Halda acquisition signals accelerating capital redeployment toward pharma, validating DePuy spinoff thesis.
MedTech Recovery Validates JNJ's Pivot Toward Pharma Dominance
MedTech Q3 5.6% growth validates DePuy spinoff thesis as cardiovascular strength signals portfolio reorientation.
DARZALEX FASPRO Approval Extends JNJ's Oncology Franchise Into Smoldering Myeloma
DARZALEX FASPRO FDA approval for smoldering multiple myeloma establishes JNJ's first-mover advantage in oncology early-intervention market segment.
IMAAVY Clinical Validation Offsets Talc Litigation Tail Risk
IMAAVY head-to-head clinical data validates myasthenia gravis differentiation, while $20M talc verdict signals persistent litigation exposure.
Johnson & Johnson Q3 Beat Fuels Orthopedics Spinoff, Icotrokinra Breakthrough
JNJ delivers Q3 beat-and-raise quarter while announcing DePuy Synthes separation, validating pharma-led growth thesis as icotrokinra breakthrough strengthens.
Johnson & Johnson’s $10 Billion Baby Powder Battle: Will It Endure?
An in‐depth update on [JNJ](/dashboard/companies/JNJ)’s legal challenges, pipeline developments and strategic initiatives, with actionable insights for investors.
Johnson & Johnson: Baby Powder Settlement, Pipeline Updates, and Market Impact
A detailed update on JNJ’s legal battles, pipeline shifts, and market performance as the company navigates key challenges.
Johnson & Johnson: Key Developments, Market Impact, and Industry Trends
Johnson & Johnson navigates legal battles, innovation, and market shifts. Key developments include baby powder litigation and Varipulse rollout. Stay informed.
J&J Under Pressure: Stelara Biosimilar Arrives as TREMFYA Shows Promise
Johnson & Johnson navigates biosimilar competition, promising TREMFYA data, and legal challenges amid a dynamic healthcare landscape.
Johnson & Johnson: Developments, Market Impact, and Industry Trends
Analysis of Johnson & Johnson's developments, market impact, and industry trends. Explore the baby powder settlement, biosimilar competition, and TREMFYA's potential.
Johnson & Johnson (JNJ): Navigating Biosimilars, Legal Battles, and Innovation
Johnson & Johnson navigates biosimilar competition, legal battles, and pharmaceutical innovations, impacting its market position and financial health.
Johnson & Johnson (JNJ): Navigating Biosimilars, Acquisitions, and Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and legal challenges in a dynamic healthcare market. Analysis and key insights provided.
Johnson & Johnson (JNJ): Navigating Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and market trends, impacting investors. Stay informed with our in-depth analysis.
Johnson & Johnson (JNJ): Strategic Shifts, Dividends, and Market Outlook
An intraday snapshot on March 5, 2025 detailing JNJ’s leadership transitions, dividend strategy, and innovative product launches.
Johnson & Johnson (JNJ): MedTech Expansion Offsets R&D Setbacks in 2025
Johnson & Johnson faces mixed outlook in 2025. R&D setbacks offset by MedTech growth. Dividend Aristocrat status provides stability amid market volatility.
Johnson & Johnson (JNJ): Icotrokinra's Promise, Setbacks, and Resilience
JNJ navigates a dynamic healthcare landscape with Icotrokinra's promise, Aticaprant's setback, and strategic acquisitions, influencing market resilience.
Johnson & Johnson (JNJ) Analysis: Pipeline, Dividends, Volatility
Analysis of Johnson & Johnson's pipeline shifts, Icotrokinra's potential, Aticaprant's setback, and dividend stability amidst market volatility.
Johnson & Johnson (JNJ): Innovation, Legal Challenges & Market
Comprehensive analysis of Johnson & Johnson (JNJ) examining Icotrokinra's clinical trial results, Kenvue spin-off, ChemImage lawsuit, R&D spending, and defensive stock characteristics.
Johnson & Johnson (JNJ): Nipocalimab, Lawsuits, and Dividend Outlook
Johnson & Johnson (JNJ) faces a mix of promising drug developments, legal challenges, and dividend sustainability concerns. Nipocalimab's FDA Fast Track contrasts with Stelara biosimilar risks.
Johnson & Johnson (JNJ): FDA Approval, US Investment & Market Impact
JNJ is making headlines with Tremfya's FDA approval for Crohn's, a $55B U.S. investment, and oncology advancements. A dividend aristocrat offering stability.
Johnson & Johnson: $55B Investment, Tremfya Approval, and Dividend King Status
Analysis of Johnson & Johnson's $55B U.S. investment, Tremfya's FDA approval for Crohn's, and its Dividend King status. Growth strategy & market impact insights.
Johnson & Johnson (JNJ): Innovation, Market Impact, and Future Outlook
Johnson & Johnson (JNJ) is navigating a dynamic market. Breakthroughs in oncology and neurology, plus U.S. investments, position JNJ for growth.
Johnson & Johnson (JNJ): Litigation, Acquisitions, and Investor Outlook
Johnson & Johnson (JNJ) navigates talc litigation setbacks and expands into neuropsychiatry with the Intra-Cellular Therapies acquisition. A look at valuation and investor outlook.
Johnson & Johnson (JNJ): TREMFYA®, Acquisitions, and Market Analysis
Analysis of Johnson & Johnson (JNJ): TREMFYA® efficacy, Intra-Cellular Therapies acquisition, market resilience, and talc litigation impacts on JNJ stock.
Johnson & Johnson: Nipocalimab, DARZALEX®, and Economic Outlook
JNJ navigates innovation, economic challenges, and strategic dividend decisions. Nipocalimab's potential in gMG and DARZALEX®'s impact on multiple myeloma are key.
Johnson & Johnson's Q1 2025 Operational Strength and Strategic AI Pivot
JNJ reports strong Q1 2025 operational growth, raises dividend, and refines AI strategy despite FY2024 reported earnings impact from special items. Analysis of financials and pipeline.
Johnson & Johnson: Navigating Legal Headwinds and Pipeline Shifts
Analysis of Johnson & Johnson's Q1 2025 earnings, talc litigation impact, pipeline updates, financial health, and dividend outlook.
Johnson & Johnson (JNJ): Pipeline Breakthroughs and Strategic Growth
Johnson & Johnson's latest clinical trials show promising results for Bleximenib in AML and TREMFYA in PsA, reinforcing its strategic growth in oncology and immunology.
Johnson & Johnson (JNJ): 2025 Strategic Moves and Financial Resilience
Johnson & Johnson's latest financial data reveals a robust pipeline, strategic acquisitions, and a significant dividend increase, navigating biosimilar pressures.
Johnson & Johnson (JNJ): Financials, Clinical Advances & Market Outlook
Johnson & Johnson's recent clinical breakthroughs in oncology and significant financial shifts redefine its market trajectory.
Johnson & Johnson's Oncology Breakthroughs: Market Impact & Strategic Insights
JNJ's latest clinical trial successes in hematologic cancers, including bispecific antibodies and CAR T-cell therapy, signal robust pipeline growth amidst evolving market dynamics.
Johnson & Johnson (JNJ): Navigating Legal Headwinds Amidst Clinical Breakthroughs
JNJ faces legal setbacks from a recent $8M talc verdict, while simultaneously celebrating major oncology breakthroughs and strategic acquisitions driving future growth.
JNJ Stock: Pharma Innovation Fuels Growth Amidst Litigation Overhang
Johnson & Johnson leverages robust pharmaceutical innovation to drive growth while navigating litigation, reinforcing its Dividend King status.
Johnson & Johnson (JNJ): Financial Strength Amidst Strategic Evolution
Explore Johnson & Johnson's latest financial performance, strategic shifts in Pharma and MedTech, dividend strength, and the ongoing talc litigation impact.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update: Pipeline Strength Amid MedTech Challenges
Explore Johnson & Johnson's recent financial performance, pipeline innovation, MedTech segment headwinds, and dividend sustainability in this detailed analysis.
Johnson & Johnson (JNJ) Q2 2025 Update: Navigating Innovative Medicine Growth Amid Stelara LOE and Legal Challenges
Johnson & Johnson's Q2 2025 highlights focus on innovative medicine growth, Stelara patent expiry impacts, MedTech dynamics, and ongoing talc litigation risks.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update: Earnings, M&A, and Market Position
Explore Johnson & Johnson's recent financial results, strategic acquisitions, and market positioning with detailed insights into earnings, cash flow, and competitive landscape.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update - Market Insights
Johnson & Johnson's recent financial results and strategic moves reveal key trends shaping its market position and investor outlook in 2025.
Johnson & Johnson Q2 2025 Analysis: Navigating Patent Headwinds with Pipeline and Diversification
Johnson & Johnson faces a $2B Q2 2025 headwind from Stelara's patent loss, offset by a strong pharma pipeline and MedTech growth, sustaining dividends and resilience.
Johnson & Johnson (JNJ) Q2 2025 Earnings Beat and Guidance Raise Fuel Growth in Innovative Medicine and MedTech
Johnson & Johnson (JNJ) delivers a strong Q2 2025 earnings beat, driven by Oncology, Neuroscience, and MedTech, raising full-year guidance amid biosimilar challenges.
Johnson & Johnson Latest Corporate Developments and Financial Analysis 2025 | Monexa AI
Explore Johnson & Johnson's latest Q2 2025 financial results, strategic moves, and market positioning with data-driven insights for informed investing.
Johnson & Johnson (JNJ) Analysis: Pipeline Wins & Financial Health
Deep dive into Johnson & Johnson's 2025, analyzing key clinical trial successes, regulatory milestones, financial performance, and strategic positioning amidst competitive shifts.
Johnson & Johnson (JNJ) Financial Analysis: Strategic Resilience Amid Drug Price Pressures
Johnson & Johnson navigates drug price pressures with diversified growth, robust pipeline, and strong financials, sustaining shareholder value despite regulatory headwinds.
Johnson & Johnson (JNJ) Q2 2025 Growth Surge and Strategic Developments Analysis
Johnson & Johnson's Q2 2025 earnings beat estimates with strong oncology and MedTech growth, raised guidance, and resilient fundamentals amid litigation risks.
Johnson & Johnson (JNJ) Q2 2025 Earnings Beat and Strategic Growth in Oncology & MedTech
Johnson & Johnson's Q2 2025 earnings beat and raised guidance driven by Oncology and MedTech growth, offsetting legal challenges and supporting a resilient financial outlook.
Johnson & Johnson Q2 2025 Analysis: Pharma Growth, MedTech Innovation & Strategic Resilience
Explore Johnson & Johnson's Q2 2025 earnings beat, pharma segment growth, MedTech advances, and pipeline catalysts amid biosimilar competition and updated guidance.
Johnson & Johnson Q2 2025 Analysis: Pharma Growth, Pipeline Strength & Dividend Stability | Monexa AI
Explore Johnson & Johnson's Q2 2025 pharma growth drivers, pipeline prospects, and dividend sustainability amid market shifts and biosimilar competition.
Johnson & Johnson: $2.0B Reshoring Gamble Meets Falling Net Income — What the Numbers Say
JNJ committed **$2.0B** to U.S. manufacturing while FY2024 revenue rose to **$88.82B** and net income plunged **-59.99%** to **$14.07B** — reshoring vs. structural headwinds.
Johnson & Johnson: Cash Flow Strength and Litigation Overhang
JNJ’s FY2024 figures show **$88.82B** revenue, **$19.84B** free cash flow and **$12.53B** net debt — strong cash generation but litigation and metric discrepancies raise investor questions.
Johnson & Johnson's Oncology Breakthroughs Drive Strategic Focus
Explore J&J's latest clinical trial successes in prostate cancer and multiple myeloma, their strategic impact, financial health, and dividend outlook.
Johnson & Johnson: Cash-Flow Strength Amid GAAP Earnings Volatility
JNJ posted a -59.97% GAAP net income drop to $14.07B in FY2024 while generating **$19.84B** free cash flow — a divergence that reframes the investment case.
Johnson & Johnson: Inlexzoh FDA Win, 2024 Financial Reconciliation and Oncology Upside
JNJ’s Inlexzoh approval and blockbuster projections collide with a sharp 2024 net‑income drop; free cash flow and a strong balance sheet frame the path to commercial execution.
Johnson & Johnson: Talc Verdict Shadow Falls as Immunology Franchise Surges Ahead
JNJ faces $966M talc verdict while TREMFYA wins first pediatric IL-23 approval, setting up pivotal Q3 earnings amid legal and operational crosscurrents.